Dual-chamber Patient-controlled Analgesia for Postoperative Recovery

Launched by SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL · Jun 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help manage pain and reduce nausea after surgery for women with severe obesity. Specifically, it looks at how well a pain relief method using two medicines—fentanyl and ketorolac—delivered through a special device controlled by the patient works after a type of weight-loss surgery called laparoscopic sleeve gastrectomy. The goal is to find out if this combined approach can better control pain and lower the chances of feeling sick or vomiting after surgery.

Women between 19 and 65 years old who are having this surgery and want to use intravenous patient-controlled pain relief (meaning they can control their own pain medicine through a device after surgery) may be eligible. However, certain health conditions like allergies to the medicines used, liver or kidney problems, asthma, or other specific medical issues may exclude someone from participating. If you join the study, you can expect to receive pain medication through a device that allows you to manage your pain relief after surgery, and the researchers will monitor your pain levels and any side effects like nausea. This study is currently looking for participants, so if you or a family member fits the criteria, you might want to ask your doctor about joining.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Adult females aged 19 to 65 years
• • American Society of Anesthesiologists physical status (ASA class) 1 to 3
• • Patients scheduled for laparoscopic sleeve gastrectomy under general anesthesia
• • Patients requesting the use of IV-PCA after surgery
• Exclusion Criteria:
• • Patients with hypersensitivity to the drugs used in this study (Ketorolac, Fentanyl)
• • Patients with alcohol or drug dependence, long-term use of opioids or analgesics
• • Patients with liver disease or renal failure
• • Patients with peptic ulcer, patients with gastrointestinal bleeding predisposition
• • Patients with suspected cerebrovascular hemorrhage, organic disorders of the head related to increased intracranial pressure
• • Patients with bronchial asthma or bronchospasm symptoms
• • Patients with severe respiratory depression
• • Nasal polyps, angioedema
• • Patients with or history of convulsive disease
• • Patients for whom the use of neuromuscular blocking agents is contraindicated